Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Renal Impairment: early-phase trial registry
7 of 33 indexed Renal Impairment trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #463 of 28,707 conditions by registered trial count.
33 US clinical trials · 7 currently recruiting · #463 of 28,707 conditions by registered trial count
Renal Impairment: 33 US clinical trials tracked, 7 recruiting.
Renal Impairment is the subject of 33 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 32 in Phase 1-2 (earlier-stage). The most active sponsor is Pfizer, running 3 of these trials.
Enrollment posture brief
Registry condition renal-impairment
OPEN 7 | RECR 21% | LATE 0 | EARLY 32 | RANK #463 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Plasma Cell Myeloma (21% recruiting · 33 trials)
Renal Impairment lists 7 open slots (21% of 33 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Renal Impairment on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Renal Impairment is recruiting below its size-band peers.
7 of 33 indexed trials (21.2%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Renal Impairment trials is spread across many organizations.
Pfizer accounts for 3 of 33 trials (9.1%). 27 distinct sponsors appear on at least one study for this condition label.
-
Most Renal Impairment trials plan to enrol fewer than 100 people.
Median target enrolment is 28 among the 33 trials that report a genuine target (sentinel values excluded). 32 of those (97%) plan for fewer than 100 participants.
-
Renal Impairment research is mostly interventional.
33 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
33 total, page 1 of 1
Groundbreaking Renal Assist Device Intervening to ENhance cardioThoracic Surgery Outcomes
3ive Labs
NCT07017933
Investigation of the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD2373)
AstraZeneca
NCT07154901
A Study of S-892216-PO in Participants With Renal Impairment and Matched Controls
Shionogi
NCT07217886
Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function
Atea Pharmaceuticals
NCT06911320
A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function
Pfizer
NCT07315360
A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function
Eli Lilly and Company
NCT07426380
A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)
Merck Sharp & Dohme
NCT07348237
A Study of Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal Impairment
Eli Lilly and Company
NCT07165015
Effect of Renal Impairment on the Pharmacokinetics of NN9535
Novo Nordisk A/S
NCT00833716
A Study to Evaluate Pharmacokinetic and Safety Trial of Emraclidine in Participants With Renal Impairment Compared With Participants With Normal Renal Function
AbbVie
NCT05940402
Pharmacokinetics of LCQ908 in Patients With Renal Impairment
Novartis Pharmaceuticals
NCT01558323
To Investigate The Pharmacokinetics Of Intravenous WCK 5222 (FEP-ZID) In Patients With Renal Impairment
Wockhardt
NCT02942810
Pharmacokinetic Study of AR882 in Subjects With Various Degrees of Renal Impairment
Arthrosi Therapeutics
NCT04646889
Study OF PF-06882961 IN Participants With Type 2 Diabetes Mellitus With Varying Degrees OF Renal Impairment AND Participants Without Renal Impairment
Pfizer
NCT04616027
A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Normal Renal Function and Participants With Various Degrees of Renal Impairment
Amgen
NCT05489614
A Pharmacokinetic Study of YM178 in Normal Subjects and Those With Mild, Moderate, and Severe Renal Impairment
Astellas Pharma
NCT00750620
A Single-Dose Study to Assess the Pharmacokinetics of Cabozantinib (XL184) Capsules in Subjects With Impaired Renal Function
Exelixis
NCT01761773
Multiple Dose Study to Evaluate the Safety of Multiple Doses of Denosumab 120 mg in Adults With Severe Chronic Kidney Disease (CKD) and CKD on Dialysis
Amgen
NCT01464931
Pharmacokinetics, Safety and Tolerability of AGO178C in Subjects With Renal Deficiencies Compared With Healthy Subjects
Novartis Pharmaceuticals
NCT01459250
A Study About How ASP5354 Affects the Body in Healthy Adults and in Adults Whose Kidneys do Not Work Well
Astellas Pharma Global Development
NCT05495581
A Study to Evaluate the Drug Levels of Mezigdomide in Adult Participants With Renal Impairment
Celgene
NCT06318676
Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function (POM Renal)
Celgene
NCT01575925
Safety and Pharmacokinetics Study of MBX 2109 in Adult Subjects With Normal and Impaired Renal Function
MBX Biosciences
NCT06496217
Fruquintinib Renal Impairment Study
Hutchmed
NCT05216354
Safety, Pharmacokinetics (PK), And Hematological Activity Of AMD3100 (Plerixafor) In Subjects With Renal Impairment
Genzyme, a Sanofi Company
NCT00445302
Study to Assess the Plasma Concentration of Tolebrutinib Given as a Tablet to Adult Participants With Renal Impairment Compared to Healthy Participants.
Sanofi
NCT05282030
Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Systolic Cardiomyopathy (Aim2)
Mayo Clinic
NCT01970176
Evaluation of Effect of Renal Impairment on the PK of Tenofovir Exalidex
ContraVir Pharmaceuticals
NCT03284164
A Single Dose Evaluation of the Effects of Renal Impairment on Deflazacort Pharmacokinetics
PTC Therapeutics
NCT02286622
A Study to Learn How the Body Processes the Study Medicine Called PF-07923568 in People With Loss of Kidney Function
Pfizer
NCT06037031
Phase 1 Study of PK and Safety of HM15912 (Sonefpeglutide) in Subjects With Normal and Severe Kidney Function
Hanmi Pharmaceutical Company Limited
NCT05711381
Single-Dose Study to Evaluate the PKs of Pretomanid in Participants With Renal Impairment Compared to Participants With Normal Renal Function
National Institute of Allergy and Infectious Diseases (NIAID)
NCT03896750
A Study to Evaluate the Safety and Pharmacokinetics of BMS-986177 in Participants With End-stage Renal Dysfunction on Chronic Stable Hemodialysis Treatment
Bristol-Myers Squibb
NCT02902679
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 32 |
Top Sponsors
Named interventions
Most-linked intervention names on Renal Impairment records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Renal Impairment trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Renal Impairment page
33 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 7 Renal Impairment trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Pfizer sponsors the most Renal Impairment trials on record, review their full trial history before evaluating a specific study. See Pfizer's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Renal Impairment condition card totals 33 registered trials; most-linked intervention YM178; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.